A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
← catalyst calendarSponsored by Alector Inc. (industry) · ALEC — their whole pipeline →. With GlaxoSmithKline.
Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
119actual
Sites
44
Countries
Argentina, Australia, Belgium +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The trial did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR® plus NACC FTLD-SB)
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-07-23 | actual | When the study began enrolling |
| Primary completion | 2025-09-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-06 | actual | The whole study's end, after follow-up |
| First posted | 2020-05-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Frontotemporal Dementia
Interventions
- Drug: AL001
- Drug: Placebo
- Drug: Open label - AL001
Primary outcome
what the primary-completion date above is the date OFEvaluation of efficacy of AL001 as measured by the CDR® plus NACC FTLD-SB
measured Through study completion, on average up to 96 weeks
Permalink · ALEC's whole pipeline · Catalyst calendar · Every registered study · What changed